Long-Acting Buprenorphine Injection Shows Promise, but Experts Urge Holistic Approach to Opioid Treatment
A long-acting injectable medication for opioid dependence is being described as a potential breakthrough in treatment, with new research suggesting it may reduce strain on healthcare services and outperform some standard therapies. However, experts caution that the medication—known as Buvidal—should not be viewed as a standalone fix, but rather as one component of a broader, person-centered system of care.
The global opioid crisis continues to affect millions. In 2023, an estimated 60 million people worldwide were using unregulated opioids. In England alone, nearly 330,000 adults were in contact with drug and alcohol treatment services between April 2024 and March 2025, with opioids accounting for a significant proportion of treatment demand.
A shift from daily dosing to long-acting treatment
In the UK, methadone and buprenorphine are the two primary medications used to treat opioid dependence. These therapies help manage cravings and withdrawal symptoms without producing intense euphoria. However, both typically require supervised daily dosing, which can be costly, time-consuming, and stigmatizing for patients.
Buvidal offers a different approach. It is a prolonged-release formulation of buprenorphine administered as a weekly or monthly injection, eliminating the need for daily pharmacy or clinic visits. For many patients, this change can be transformative, removing the daily burden of medication pickup and reducing the visibility of treatment routines that can carry stigma.
The medication was recommended for use in England by the National Institute for Health and Care Excellence (NICE) in 2019, with some specialist and GP services adopting it. Its broader rollout accelerated during the COVID-19 pandemic, when healthcare systems needed alternatives that allowed for continuity of care without frequent in-person visits.
Evaluating impact in Wales
A new report commissioned by the Welsh Government and led by researchers at the University of South Wales (USW), in collaboration with the University of Hertfordshire and Wrexham University, examined how Buvidal has been implemented in Wales and whether it lives up to its reputation as a “game-changer.”
Professor Katy Holloway of USW said the evaluation reveals both the strengths of the medication and the importance of the treatment environment in which it is delivered.
“Our research provides a detailed picture of how Buvidal treatment has evolved in Wales,” she explained. “For many individuals, it creates a sense of stability and breathing space that daily supervised treatment does not always allow. It can ease the constant pressure of managing withdrawal and attending appointments, giving people more room to focus on work, relationships, and recovery. But it is not a cure-all. The broader context of a person’s substance use remains critical.”
Reduced healthcare use and strong retention
The report found encouraging evidence of high treatment retention, reduced opioid use, and positive patient experiences—particularly among those who struggled with daily supervised dosing.
Professor Fabrizio Schifano, Professor of Clinical Pharmacology at the University of Hertfordshire, highlighted another significant finding: patients receiving Buvidal tended to use healthcare services less frequently than those on methadone or oral buprenorphine.
“This translated into lower healthcare utilization costs for the NHS,” he said. “The most notable reductions were seen in ambulance service use.”
These findings suggest that long-acting injectable buprenorphine could not only improve patient outcomes but also ease pressure on overstretched healthcare systems.
Not a standalone solution
Despite these benefits, the evaluation underscores that Buvidal’s success depends heavily on how it is implemented. Some patients reported difficulties during the initial transition onto the medication. Others continued to use additional substances, often linked to boredom, isolation, or unresolved trauma.
Service providers noted that staff training, clinical confidence, and adequate resources significantly influenced patient experiences. Without proper support, the medication alone may not address the deeper drivers of substance use.
The report arrives at a time when opioid-related harms remain a pressing public health issue across the UK, particularly amid concerns about increasingly potent synthetic opioids such as FYL appearing in illicit drug supplies.
A call for comprehensive, compassionate care
Researchers recommend that Buvidal be embedded within a wider, person-centered treatment framework that includes psychological support, meaningful social engagement, and access to wraparound services.
“This evaluation reinforces that effective treatment is about more than medication,” Professor Holloway said. “It’s about dignity, genuine choice, and addressing the root causes of substance use. Buvidal can play an important role, but it must be delivered within compassionate, well-resourced systems that provide holistic care.”
The Evaluation of Buvidal report is now available online and is expected to inform ongoing discussions among practitioners, commissioners, and policymakers shaping the future of opioid treatment across the UK.
The research team included criminologists, psychologists, a social worker, an addictions psychiatrist, a medically trained researcher, and a statistician—reflecting the multidisciplinary approach required to address a crisis as complex as opioid dependence.
Source: University of Hertfordshire